Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Biocon Limited (BIOCON.NS)
INR434.60
-2.70 (-0.62%)
IN NSE Healthcare Biotechnology
Address
20th KM, Hosur Road 560100
Bengaluru, IN
Bengaluru, IN
CEO
Shreehas Pradeep Tambe MTech
Website
biocon.com
IPO
2004-04-07
ISIN INE376G01013
Also trades on
Bombay Stock Exchange · BIOCON.BO (INR)
National Stock Exchange of India · BIOCON.NS (INR)
Description
Biocon Limited functions as a biopharmaceutical firm, engaged in the production of pharmaceutical, medicinal chemical, and plant-derived products. Its business activities are organized into distinct segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company dedicates its efforts to crucial therapeutic domains, including diabetes, oncology, immunology, ophthalmology, and bone health disorders. Furthermore, Biocon provides comprehensive services encompassing the discovery, development, and manufacturing of both small and large molecules. With a wide international presence, it caters to customers in roughly 120 nations. Headquartered in Bengaluru, India, Biocon Limited commenced operations in 1978.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR434.60
-2.70 (-0.62%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
0.31
Float Shares
583.07M
Free Float %
45.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.93% | +5.43% | +8.63% | +2.06% | -0.90% | -3.86% | +15.40% | +53.60% | -1.51% | +267.31% | +838.77% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
434.60
DCF (Unlevered)
836.12
+92.4%
DCF (Levered)
104.83
-75.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
63% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 9 | 0 |
| Hold | 2 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 4 | 0 |
Quality scores
Altman Z-Score
1.47
Distress
Piotroski F-Score
7 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
2 / 5
Medium
ROA Score
3 / 5
Medium
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+10.9% ★ Q1'26: +2.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-66.7% Q1'26: -72.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-3.2% Q1'26: -1.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+8.9% ★ Q1'26: +11.2% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+2.6% ★ Q1'26: +3.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+14.2% Q1'26: +32.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×4.47× Q1'26: 3.78× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2010 actual |
Mar 2011 actual |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 16 Rev. Ana. 11 EPS Ana. |
Mar 2027 18 Rev. Ana. 14 EPS Ana. |
Mar 2028 15 Rev. Ana. 10 EPS Ana. |
Mar 2029 2 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
20.36B
est: 23.42B (-13.1%)
|
23.01B
est: 27.67B (-16.9%)
|
20.49B
est: 20.09B (+2.0%)
|
24.85B
est: 24.68B (+0.7%)
|
30.90B
est: 29.46B (+4.9%)
|
30.90B
est: 30.37B (+1.7%)
|
33.47B
est: 34.24B (-2.2%)
|
38.91B
est: 40.65B (-4.3%)
|
41.23B
est: 41.74B (-1.2%)
|
55.14B
est: 56.58B (-2.5%)
|
63.01B
est: 66.75B (-5.6%)
|
71.43B
est: 73.90B (-3.3%)
|
81.84B
est: 80.05B (+2.2%)
|
111.74B
est: 109.10B (+2.4%)
|
147.56B
est: 147.66B (-0.1%)
|
152.62B
est: 149.30B (+2.2%)
|
169.94B
167.13B – 177.86B
+13.8% YoY
|
201.95B
191.11B – 211.78B
+18.8% YoY
|
229.05B
228.41B – 229.69B
+13.4% YoY
|
262.84B
257.21B – 268.47B
+14.8% YoY
|
| EBITDA |
5.09B
est: 3.04B (+67.0%)
|
6.28B
est: 5.56B (+12.9%)
|
5.73B
est: 4.44B (+29.3%)
|
5.67B
est: 7.23B (-21.6%)
|
6.90B
est: 9.44B (-26.9%)
|
6.90B
est: 7.33B (-5.9%)
|
7.63B
est: 9.11B (-16.3%)
|
9.82B
est: 11.69B (-16.0%)
|
8.27B
est: 12.21B (-32.3%)
|
13.92B
est: 14.35B (-3.1%)
|
15.94B
est: 21.68B (-26.5%)
|
16.52B
est: 19.44B (-15.0%)
|
19.56B
est: 24.44B (-20.0%)
|
26.57B
est: 30.01B (-11.5%)
|
32.71B
est: 32.70B (+0.0%)
|
31.24B
est: 33.22B (-6.0%)
|
37.63B
37.01B – 39.39B
+13.3% YoY
|
44.72B
42.32B – 46.90B
+18.8% YoY
|
50.73B
50.58B – 50.87B
+13.4% YoY
|
58.21B
56.96B – 59.45B
+14.8% YoY
|
| EBIT |
3.68B
est: 3.25B (+13.3%)
|
4.71B
est: 4.03B (+16.8%)
|
3.98B
est: 2.97B (+33.8%)
|
3.91B
est: 4.21B (-7.2%)
|
4.75B
est: 7.08B (-32.9%)
|
4.75B
est: 5.57B (-14.7%)
|
5.19B
est: 6.92B (-25.0%)
|
7.05B
est: 8.13B (-13.3%)
|
4.44B
est: 7.27B (-39.0%)
|
9.46B
est: 6.00B (+57.7%)
|
10.52B
est: 11.20B (-6.1%)
|
9.54B
est: 12.63B (-24.5%)
|
11.58B
est: 15.87B (-27.0%)
|
15.64B
est: 19.49B (-19.7%)
|
17.83B
est: 17.48B (+2.0%)
|
15.43B
est: 17.76B (-13.1%)
|
20.12B
19.79B – 21.06B
+13.3% YoY
|
23.91B
22.63B – 25.08B
+18.8% YoY
|
27.12B
27.04B – 27.20B
+13.4% YoY
|
31.12B
30.46B – 31.79B
+14.8% YoY
|
| Net Income |
2.93B
est: 1.35B (+117.4%)
|
3.68B
est: 3.46B (+6.1%)
|
3.38B
est: 2.67B (+26.8%)
|
5.09B
est: 4.16B (+22.4%)
|
4.14B
est: 6.08B (-31.9%)
|
4.97B
est: 4.31B (+15.4%)
|
8.96B
est: 5.61B (+59.7%)
|
6.12B
est: 6.49B (-5.7%)
|
3.72B
est: 6.32B (-41.1%)
|
9.05B
est: 5.03B (+79.9%)
|
7.48B
est: 10.72B (-30.2%)
|
7.41B
est: 8.99B (-17.6%)
|
6.48B
est: 11.30B (-42.6%)
|
4.63B
est: 4.20B (+10.2%)
|
10.23B
est: 18.01B (-43.2%)
|
10.13B
est: 2.32B (+335.9%)
|
4.86B
3.13B – 7.68B
+109.0% YoY
|
14.04B
8.59B – 14.91B
+189.1% YoY
|
18.67B
12.30B – 26.54B
+33.0% YoY
|
18.32B
17.84B – 20.39B
-1.9% YoY
|
| SGA |
4.80B
est: 2.98B (+61.2%)
|
—
est: 3.29B (-100.0%)
|
1.35B
est: 2.58B (-47.8%)
|
6.00B
est: 4.45B (+35.0%)
|
5.37B
est: 5.36B (+0.2%)
|
5.37B
est: 6.28B (-14.5%)
|
6.13B
est: 7.93B (-22.7%)
|
7.51B
est: 9.34B (-19.6%)
|
9.31B
est: 10.09B (-7.8%)
|
11.65B
est: 17.39B (-33.0%)
|
16.55B
est: 20.28B (-18.4%)
|
17.49B
est: 17.53B (-0.2%)
|
20.54B
est: 22.03B (-6.8%)
|
23.33B
est: 27.06B (-13.8%)
|
28.53B
est: 32.00B (-10.8%)
|
34.98B
est: 32.50B (+7.6%)
|
36.82B
36.21B – 38.54B
+13.3% YoY
|
43.76B
41.41B – 45.89B
+18.8% YoY
|
49.63B
49.49B – 49.77B
+13.4% YoY
|
56.95B
55.73B – 58.17B
+14.8% YoY
|
| EPS |
2.51
est: 2.46 (+2.2%)
|
3.13
est: 3.01 (+4.0%)
|
2.88
est: 2.72 (+5.8%)
|
4.33
est: 2.92 (+48.3%)
|
3.52
est: 3.42 (+2.9%)
|
4.14
est: 3.31 (+25.2%)
|
4.67
est: 3.96 (+18.1%)
|
5.20
est: 5.45 (-4.6%)
|
3.16
est: 3.23 (-2.3%)
|
7.65
est: 7.24 (+5.7%)
|
6.32
est: 7.35 (-14.0%)
|
6.24
est: 6.10 (+2.2%)
|
5.44
est: 5.94 (-8.5%)
|
3.88
est: 5.38 (-27.9%)
|
8.55
est: 13.21 (-35.3%)
|
8.46
est: 1.71 (+396.1%)
|
4.02
2.29 – 5.61
+136.0% YoY
|
8.63
6.28 – 10.90
+114.4% YoY
|
13.08
9.00 – 19.41
+51.6% YoY
|
14.02
13.04 – 14.91
+7.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
14.05B
OE per share TTM
11.31
Owner's Yield
2.32%
Maintenance CapEx ratio
271.91%
Maint CapEx / Avg PPE
93.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 18 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Schwab Emerging Markets Equity ETF SCHE | 0.03% | 3.88M | 0.06% |
| 2 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.03% | 1.58M | 0.17% |
| 3 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.03% | 1.58M | 0.17% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.03% | 864.3K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.03% | 383.2K | 0.48% |
| 6 | Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX | 0.02% | 148.7K | 0.40% |
| 7 | Vanguard All-World ex-US Shares Index ETF VEU.AX | 0.01% | 341.8K | 0.04% |
| 8 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 55.0K | 0.24% |
| 9 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 55.0K | 0.24% |
| 10 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 68.5K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
918.5K
Shares Outstanding
1.27B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Siddharth Mittal | MD, Chief Executive Officer & Director | 74M | male |
| Kiran Mazumdar Shaw | Founder & Executive Chairperson | 42M | female |
| Rajesh Shanoy | Company Secretary & Compliance Officer | 6M | male |
| Kedar Narayan Upadhye | Chief Financial Officer | — | male |
| Mandar S. Ghatnekar | Chief Technology Officer | — | — |
| Maninder Kapoor Puri | Head of Human Resources | — | female |
| Maninder Singh Puri | Head of Human Resources | — | female |
| Abhijit Zutshi | Chief Commercial Officer | — | male |
| Naveen Narayanan | Chief Human Resources Officer | — | male |
| Paul Vazhayil Thomas | Chief Commercial Officer, U.S. & Portfolio Strategy & Business Dev, Adv mkts of Biosimilars Business | — | male |
| Saurabh Paliwal | Head of Investor Relations | — | male |
| Seema Shah Ahuja | SVP & Global Head Corporate Communications & Corporate Brand Biocon Group | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BIOCON.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
